Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $225,919 | 12 | 99.7% |
| Unspecified | $618.00 | 1 | 0.3% |
| Food and Beverage | $44.30 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | $98,500 | 5 | $0 (2019) |
| The Medicines Company | $78,400 | 1 | $0 (2018) |
| Melinta Therapeutics, LLC | $41,544 | 2 | $0 (2024) |
| Shionogi Inc | $4,969 | 3 | $0 (2017) |
| PFIZER INC. | $2,550 | 2 | $0 (2017) |
| Astellas Pharma Global Development | $618.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41,500 | 1 | Melinta Therapeutics, LLC ($41,500) |
| 2019 | $98,500 | 5 | TETRAPHASE PHARMACEUTICALS, INC. ($98,500) |
| 2018 | $79,062 | 3 | The Medicines Company ($78,400) |
| 2017 | $7,519 | 5 | Shionogi Inc ($4,969) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/09/2024 | Melinta Therapeutics, LLC | Vabomere (Drug) | Consulting Fee | Cash or cash equivalent | $41,500.00 | General |
| Category: ANTIBIOTICS | ||||||
| 10/04/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Consulting Fee | Cash or cash equivalent | $8,000.00 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 05/31/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Consulting Fee | Cash or cash equivalent | $8,000.00 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 03/28/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 02/21/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Consulting Fee | Cash or cash equivalent | $26,500.00 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 01/10/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Consulting Fee | Cash or cash equivalent | $53,500.00 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 05/04/2018 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $618.00 | Research |
| Study: HEOR • Category: INFECTIOUS DISEASES | ||||||
| 04/21/2018 | Melinta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $44.30 | General |
| 01/12/2018 | The Medicines Company | VABOMERE (Drug) | Consulting Fee | Cash or cash equivalent | $78,400.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/19/2017 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $1,005.00 | General |
| 09/18/2017 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 07/06/2017 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $1,340.00 | General |
| 05/15/2017 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 03/09/2017 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $2,624.17 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| HEOR | Astellas Pharma Global Development | $618.00 | 1 |
About Dr. Marya Zilberberg, M.D
Dr. Marya Zilberberg, M.D is a Pulmonary Disease healthcare provider based in Leeds, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1336292879.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marya Zilberberg, M.D has received a total of $226,581 in payments from pharmaceutical and medical device companies, with $41,500 received in 2024. These payments were reported across 14 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($225,919).
Practice Information
- Specialty Pulmonary Disease
- Location Leeds, MA
- Active Since 01/19/2007
- Last Updated 07/08/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1336292879
Products in Payments
- Xerava (Drug) $98,500
- VABOMERE (Drug) $78,400
- Vabomere (Drug) $41,500
- CRESEMBA (Drug) $618.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.